Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 3/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28405423 | 0.87 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL13177515 | 0.85 | SLC6A12 (0.42) | SLC6A12SLC6A11SLC6A13SLC1A2MEN1 | |
| SCHEMBL6274503 | 0.84 | EPHX1 (0.38) | EPHX1 | |
| SCHEMBL6805501 | 0.79 | TRPM8 (0.38) | KMT2A | |
| SCHEMBL25406478 | 0.77 | ACHE (0.30) | — | |
| SCHEMBL6271391 | 0.77 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL28405425 | 0.76 | — | — | |
| SCHEMBL12993394 | 0.76 | — | — | |
| SCHEMBL1861904 | 0.76 | — | — | |
| SCHEMBL25678378 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606244-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| WO-2004037769-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | SLC6A12 1776/4885SLC6A11 180/4885SLC6A13 224/4885 |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | SLC6A12 1776/4885SLC6A11 180/4885SLC6A13 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.